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Patient and Methods: Twenty-four patients with completely resected 
stage I-IIIA non-small lung cancer were administered 3 cycles of 
adjuvant chemotherapy consisting of carboplatin at an AUC of 4 and 
gemcitabine at dose 1000mg/m2 on day 1 and 15, in a 4-week cycle. 
Patients’ average age was 56.5 years and 96% of patients had ECOG 
performance status 0; 41.6% had pathological stage IIIA and 58.4% 
stage IB and II. Histologic tumor subtype was: 62.5% adenocarcinoma, 
33.3% squamous cell carcinoma and 4.1% large-cell undifferentiated 
carcinoma.
Results: All patients enrolled in the study received the planned 3 
cycles of adjuvant chemotherapy (compliance 100%). Myelotoxicity 
of all grades was observed in 8(33.3%) patients; grade 1-2 anemia in 
7(29%), grade 1-3 thrombocytopenia in 2(8.3%) and grade 1 leucope-
nia in 1(4.1%). G-CSF at dose 33.6miu/day s.b. was administered on 
D4-D6 and D18-D20 of each cycle. Non-hematologic toxicity consist-
ed of all grade nausea/vomiting(12.5%) and all grade diarrhea(8.3%). 
No treatment-related death was observed. The 2-year survival rate was 
87.5%, and especially for stage IIIA patients 70%. A 5-year follow-up 
is ongoing.
Conclusions: We identiﬁed a comparable efﬁcacy of adjuvant 
Carboplatin+Gemcitabine combination regimen with the one observed 
with Cisplatin-based chemotherapy regimens, however exhibiting a 
better toxicity proﬁle and a high standard of compliance. 
P2-170 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
Twice a day radiation therapy concomitant chemotherapy in 
locally advanced non small cell lung cancer
Chauhan, Ashok1 Singh, Harmeet1 Manocha, Krishan K.2 Chawla, 
Harish1 
1 Dept of Radiotherapy, Post Graduate Institute of Medical Sciences, 
Rohtak, India 2 Radiation Physics, Dept of Radiotherapy, Post Gradu-
ate Institute of Medical Sciences, Rohtak, India 
Background: Combination of chemotherapy and thoracic radiation 
therapy is the best available treatment for locally advanced unresect-
able NSCLC. Results of conventional RT and CT are still not up to the 
acceptable level. We conducted a trial to compare chemotherapy given 
concurrently with twice daily external radiotherapy and conventional 
external radiotherapy alone in locally advanced NSCLC.
Methods: Fifty patients of locally advanced unresectable NSCLC were 
inducted into two arms, A & B. Twenty ﬁve patients of arm-A received 
chemotherapy with Cisplatin 75mg/m2 intravenously given starting on 
day 1 of radiation therapy for 5 courses at 3 weeks interval and vinblas-
tine 5mg/m2 given weekly for 5 courses starting on day 1 of radiation 
along with twice daily external thoracic radiation therapy. The radiation 
was given twice daily at a dose of 1.3 Gy per fraction with each frac-
tion separated by a minimum of 6 hours. A total dose of 60 Gy in 46 
fractions over 4 weeks and 3 days was delivered. Twenty ﬁve patients 
of arm-B received only conventional external radiotherapy 60Gy in 30 
fractions, 5 days a week over 6 weeks.
Results: Six weeks after the completion of treatment 67% of the 
patients in arm A showed some tumor response (27% CR; 40% PR) as 
compared to only 42% patients in the arm B. The only severe toxici-
ties observed were leucopenia (5 patients in arm A) and esophagitis, 
grade 3 (4 patients in the arm A and 3 patients in arm B). At one year 
the survival rates were 61% in arm A and 39% in the arm B. No patient 
required hospitalization due to treatment related toxicity.
Conclusion: To conclude, hyper fractionated radiotherapy and che-
motherapy regimen has promising efﬁcacy and manageable toxicity in 
unresectable advanced NSCLC.
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Background: Both local and distant failure rates are high for inoper-
able NSCLC treated by combination chemoradiation (CRT). We have 
previously reported that docetaxel (Doc) demonstrates longer G2/M 
arrest and better sub-additive effects with radiation when compared 
with paclitaxel in pre-clinical investigations. We subsequently reported 
a clinical study using pulsed low-dose paclitaxel radiosensitizing 
strategy, which yielded a 98% in-ﬁled chest tumor control rate [Clin 
Cancer Res, 9: 969-975, 2003]. With the encouraging local tumor con-
trol by pulsed taxane CRT, we conducted a phase II study using pulsed 
low-dose sensitizing Doc CRT targeting local tumor, plus one-cycle of 
induction chemotherapy (CT) of Doc/cisplatin (CP) targeting distant 
micrometastasis upfront for patients (pts) with stage III NSCLC.
Methods: Pts with inoperable stage III NSCLC were eligible. Induc-
tion CT consisted of Doc 75mg/m2 and CP 75mg/m2 on d 1 followed 
by rhG-CSF (150 ug/m2 sq on d 2 to 10). The CRT consisted of Doc 12 
mg/m2 twice/wk with daily RT, 64.8 Gy to gross tumors and 45-57.6 
Gy to subclinical disease. PK studies of Doc were performed during CT 
and during CRT in each pt. The clearance (CL), area under the plasma 
concentration versus time curve (AUC), and drug half-life (t1/2) were 
estimated.
Results: 26 pts were enrolled and 16 completed study. Overall response 
rate was 69% [50% (8/16) PR and19% (3/16) CR]. 2-year survival was 
57 %. During induction CT, primary grade (G) 3 toxicities were allergic 
reaction (10%), non-neutropenic infection (20%), nausea/vomiting 
(N/V) (10%), fatigue (10%), hypertension (5%) hyperglycemia (5%), 
dyspnea (5%) & fatigue (5%). There was no G3/4 hematologic toxicity. 
During CRT, 50% (4/8) developed grade 3 esophagitis at the initial 
twice-weekly Doc dose of 12 mg/m2. Eight subsequent pts received 
reduced Doc to 10 mg/m2 with only one grade 3 esophagitis. Other G3 
toxicities from CRT were N/V(28%), fatigue(14%), anorexia(14%), 
ﬂushing(7%), chest pain(7%), & diarrhea(7%). We observed no G3 or 4 
pneumonitis or any other G4 toxicity. Mean ± SD of Doc CL at 75 and 
10 mg/m2 was 20 ± 5 and 22 ± 10 L/h/m2, respectively. Ratio of Doc 
CL at 75 to 10 mg/m2 within a pt was 1.0 ± 0.4. Doc AUC at 75 and 10 
mg/m2 was 3,933 ± 1,028 and 566 ± 257ng/ml•h, respectively, with a 
ratio of 8.31 ± 3.84 for 75 mg/m2 to 10 mg/m2. Half-life of Doc at 75 
and 10 mg/m2 was 15.4 ± 3.7 hrs and 15.0 ± 2.2 hrs, respectively, with 
a ratio of 1.08 ± 0.15. 
Conclusions: One-cycle full-dose Doc/CP with rhG-CSF followed 
by pulsed low-dose Doc CRT is associated with promising antitumor 
activity and low hematologic toxicity. Grade 3 esophagitis was associ-
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ated with dose intensity of radiosensitizing Doc, and was diminished 
by dose reduction. Results suggest that this regimen should be further 
evaluated for stage III NSCLC. The PK disposition of Doc was similar 
at full-dose (75 mg/m2) and at low-dose (10 mg/m2 or 12 mg/m2) for 
Doc plasma clearance and half-life. Doc PK was not affected by the 
presence of cisplatin during induction CT. 
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Lung cancer in women: results of treatment
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Background: Evaluate efﬁcacy of combined surgical and conservative 
treatments women lung cancer in Lithuania. 
Matherial and Methods: From 1996-2003 y.y. 316 patients (women) 
entered study evaluating results of lung cancer treatment in Institute of 
Oncology, Vilnius University. Patients were stratiﬁed according: age, 
stage of disease, smoking status, morfology and treatment (surgery 
alone or with other treatment v/s no surgery involved). According age 
patients distribution were: 35-49 y. - 43 pts (13,6%), 50-64 y. - 124 
pts (39,2%), 65-74 y. - 108 pts (34,1%) and 75+ y. - 41 pts (12,9%). 
Morfology: adenocarcinoma - 173 pts (54,7%), epidermoid - 43 pts 
(13,6%), SCLC - 31 pts (9,8%), carcinoid - 9 pts (2,8%), cancer cells 
- 19 pts (6,0%) and nonclassiﬁed carcinoma - 41 pts (12,9%); By stage: 
I stage - 55 pts (18,4%), II stage - 66 pts (20,8%), III stage - 100 pts 
(31,6%), IV stage - 95 (30,1%); By smoking status: non smokers - 241 
pts (76,2% ), smokers - 75 pts (23,7% ). Surgery was performed in 85 
pts (26,9%), combined surgical treatment - 61 pts (19,3%), combined 
conservative treatment - 103 pts (32,6%), 67 pts (21, 2%) received 
palliation. 
Results: overall 5 years survival 23% of cases. 5 years survival by age: 
<50 y. - 18%, 50-64 y. - 20%, 65-74 y. - 19%, +75 y. - 17% cases. 5 
years survival by stage: I stage - 52%, II stage - 25%, III stage - 10%, 
IV stage - 12%. 5 years survival by morfology: adenoCa - 22%, epider-
moid - 22%, SCLC - 10%, carcinoid - 52%, cancer cells - 22%, non-
classiﬁed carcinoma - 24%. 5 years survival by smoking status: SCLC: 
smokers 5 %, non smokers - 15%; nonclassiﬁed carcinoma: smokers 
- 0%, non smokers - 26%. 5 years survival estimate by treatment: 5 
years survival: surgery±combined treatment 25% of cases, no surgery 
involved - 10% of cases. 
Conclusions: 1. Surgical or surgical combined treatment was superior 
to conservative treatment (5 years survival 25% v/s 10%). 2. Bet-
ter treatment results were achieved in carcinoid treatment (5 y. surv. 
- 52%), NSCLC - 22%, SCLC - 10% and nonclassiﬁed carcinomas 
- 24%. 3. Overall 5 y. survival in women lung cancer in this study was 
achieved in 23% of cases. 
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pathological N2 non-small cell lung cancer
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Background: Several studies have suggested that induction therapy 
followed by surgical resection may improve the outcome in patients 
with stage IIIa (N2) non-small-cell lung cancer (NSCLC), however, 
optimal induction strategy has not been deﬁned. 
Methods: We retrospectively reviewed the medical records of 33 
patients with stage IIIa NSCLC having mediastinal lymph node metas-
tases proved by mediastinoscopy. Fifteen patients received induction 
chemotherapy (CT) between 1995 and 1999. Eighteen patients received 
induction chemoradiotherapy (CRT) between 2000 and 2006. For 
induction CT, CDDP (60 mg m-2) and CPT-11 (50 mg m-2) were given 
on days 1, 8, 29, and 36. For induction CRT, cisplatin (40 mg/m2) and 
docetaxel (40 mg/m2) were given on days 1, 8, 29, and 36 along with 
concurrent thoracic irradiation at a dose of 46 Gy (2 Gy/fraction/day). 
Induction was followed by surgical resection in 4-6 weeks.
Results: Preoperative patients’ characteristics were similar between 
CT and CRT (Table 1). All 33 patients underwent surgical resection 
after the induction therapy. The rate of pathological effectiveness of 
the main tumor (the rate of Ef2 or Ef3) was signiﬁcantly higher in 
CRT than in CT (72.2% vs 26.7%, p = 0.022). Treatment related death 
was encountered in one CT patient but in none of CRT patients. The 
5-year survival rate was signiﬁcantly better in CRT (68.2%) than in CT 
(26.7%) as shown in Figure 1.
Conclusions: Induction CRT may provide signiﬁcantly better patho-
logical effectiveness than induction CT, thus may improve the survival 
for patients with stage IIIa (N2) NSCLC. 
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Background: Multimodality therapy has clearly improved outcome 
in Stage III NSCLC. However, the majority of patients still succumb 
to disease. Platinum based therapy, utilized both concurrently with 
radiotherapy as well as induction/consolidation therapy is central to 
this approach. Recent data in adjuvant therapy and in stage IV disease 
indicate that ERCC1 expression correlates with platinum responsive-
ness. BTUB isoform expression has been correlated to sensitivity to an-
titubulin agents. We utilized a novel, quantiﬁable, IF method to assess 
ERCC1 and beta tubulin III expression in pre-treatment specimens and 
correlated with overall survival from a prospective institutional study.
Methods: Pts with path III A/B disease, PS 0-1 were eligible. CMT 
consisted of induction therapy with escalating doses of Carboplatin 
(C)(AUC=1), and Vinorelbine (V) 5-15mg/m2 q wk, with concurrent 
69.6 Gy (1.2 Gy bid/5 d/wk for 29 d). Pts with negative mediasti-
nal nodes after chemoXRT underwent resection, if feasible. All pts 
received additional chemoRx consisting of C/V at AUC=5 d1, 25mg/m2 
d1,8 q 21 d X 3 followed by docetaxel 75mg/m2 2 q 21 d x 3. Parafﬁn 
embedded tumor specimens were analyzed by IF staining for ERCC1 
and BTUB. Anti-ERCC-1 was directly labeled with Alexa 594 while 
anti-beta-tubulin was counterstained with Alexa 532 dye. IF was 
measured quantitatively with a computerized microscopy system and 
expressed as the mean of the average ﬂuorescence per pixel. IF expres-
sion in the tumor sections is measured in 1000 tumor cells utilizing 5 
